
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen Inc. is projected to experience accelerated sales growth throughout 2026, bolstered by commercial momentum, the implementation of a permanent J-code for reimbursement effective April 1, and increased adoption among community physicians. Management has set optimistic expectations for 1Q26 product sales, forecasting over $18 million, which indicates a remarkable sequential growth of over five-fold compared to previous quarters. The company's robust pipeline of innovative therapies and advanced manufacturing capabilities via its proprietary technology platforms further contribute to a favorable long-term outlook for its stock.
Bears say
Precigen Inc reported fourth-quarter sales of $3.4 million, significantly below analysts' consensus estimate of $8.3 million. Additionally, the company incurred a net loss of $0.04 per diluted share, which, although better than the expected loss of $0.08 per share, indicates ongoing financial challenges. These disappointing sales figures, combined with net losses, suggest potential difficulties in achieving the expected revenue growth and profitability, contributing to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares